若您需要咨询产品或有任何技术问题,请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

CFTR(inh)-172

抑制囊性纤维化跨膜传导调节剂(CFTR)

产品号 #(选择产品)

产品号 #100-0554_C

抑制囊性纤维化跨膜传导调节剂(CFTR)

总览

CFTR(inh)-172是一种有选择性且可逆的噻唑烷酮抑制剂,可作用于囊性纤维化跨膜传导调节剂(CFTR);Ki = 300 nM;Ma et al.)。CFTR是一种氯离子通道,参与许多上皮组织(如呼吸道和肠道)的液体分泌(Ma et al.)。CFTR基因缺陷会改变离子转运,可导致囊性纤维化(Dalli et al.;Ma et al.)。当将其腹腔注射到小鼠体内时,CFTR(inh)-172可抑制由霍乱毒素诱导的肠液分泌(Ma et al.)。

疾病模型
·减缓小鼠多囊肾病中的囊肿生长(Yang et al.)。

别名
囊性纤维化跨膜传导调节剂抑制剂172;CFTR抑制剂-172
 
细胞类型
气道细胞,肠道细胞
 
研究领域
疾病建模,上皮细胞研究
 
CAS 编号
307510-92-5
 
化学式
C18H10F3NO3S2
 
分子量
409.4 克/摩尔
 
纯度
≥98%
 

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明,或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Product Name
CFTR(inh)-172
Catalog #
100-0554, 100-0555
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
CFTR(inh)-172
Catalog #
100-0554, 100-0555
Lot #
All
Language
English

相关材料与文献

技术资料 (3)

文献 (3)

CFTR inhibition provokes an inflammatory response associated with an imbalance of the annexin A1 pathway. J. Dalli et al. The American journal of pathology 2010 jul

Abstract

Cystic fibrosis (CF), a disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, is characterized by chronic bacterial infections and inflammation in the lung. Having previously shown that deletion of CFTR is associated with lower expression of the endogenous anti-inflammatory protein Annexin A1 (AnxA1), we investigated further this possible functional connection using a validated CFTR inhibitor. Treatment of mice with the CFTR inhibitor-172 (CFTR(172)) augmented the acute peritonitis promoted by zymosan, an effect associated with lower AnxA1 levels in peritoneal cells. Similar results were obtained with another, chemically distinct, CFTR inhibitor. The pro-inflammatory effect of CFTR(172) was lost in AnxA1(-/-), as well as CFTR(-/-) mice. Importantly, administration of hrAnxA1 and its peptido-mimetic to CFTR(-/-) animals or to animals treated with CFTR(172) corrected the exaggerated leukocyte migration seen in these animals. In vitro assays with human Polymorphonuclear leukocyte (PMN) demonstrated that CFTR(172) reduced cell-associated AnxA1 by promoting release of the protein in microparticles. We propose that the reduced impact of the counterregulatory properties of AnxA1 in CF cells contributes to the inflammatory phenotype characteristic of this disease. Thus, these findings provide an important insight into the mechanism underlying the inflammatory disease associated with CFTR inhibition while, at the same time, providing a novel pharmacological target for controlling the inflammatory phenotype of CF.
Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. B. Yang et al. Journal of the American Society of Nephrology : JASN 2008 jul

Abstract

Cyst expansion in polycystic kidney disease (PKD) involves progressive fluid accumulation, which is believed to require chloride transport by the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Herein is reported that small-molecule CFTR inhibitors of the thiazolidinone and glycine hydrazide classes slow cyst expansion in in vitro and in vivo models of PKD. More than 30 CFTR inhibitor analogs were screened in an MDCK cell model, and near-complete suppression of cyst growth was found by tetrazolo-CFTR(inh)-172, a tetrazolo-derived thiazolidinone, and Ph-GlyH-101, a phenyl-derived glycine hydrazide, without an effect on cell proliferation. These compounds also inhibited cyst number and growth by {\textgreater}80{\%} in an embryonic kidney cyst model involving 4-d organ culture of embryonic day 13.5 mouse kidneys in 8-Br-cAMP-containing medium. Subcutaneous delivery of tetrazolo-CFTR(inh)-172 and Ph-GlyH-101 to neonatal, kidney-specific PKD1 knockout mice produced stable, therapeutic inhibitor concentrations of {\textgreater}3 microM in urine and kidney tissue. Treatment of mice for up to 7 d remarkably slowed kidney enlargement and cyst expansion and preserved renal function. These results implicate CFTR in renal cyst growth and suggest that CFTR inhibitors may hold therapeutic potential to reduce cyst growth in PKD.
Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. T. Ma et al. The Journal of clinical investigation 2002 dec

Abstract

Secretory diarrhea is the leading cause of infant death in developing countries and a major cause of morbidity in adults. The cystic fibrosis transmembrane conductance regulator (CFTR) protein is required for fluid secretion in the intestine and airways and, when defective, causes the lethal genetic disease cystic fibrosis. We screened 50,000 chemically diverse compounds for inhibition of cAMP/flavone-stimulated Cl(-) transport in epithelial cells expressing CFTR. Six CFTR inhibitors of the 2-thioxo-4-thiazolidinone chemical class were identified. The most potent compound discovered by screening of structural analogs, CFTR(inh)-172, reversibly inhibited CFTR short-circuit current in less than 2 minutes in a voltage-independent manner with K(I) approximately 300 nM. CFTR(inh)-172 was nontoxic at high concentrations in cell culture and mouse models. At concentrations fully inhibiting CFTR, CFTR(inh)-172 did not prevent elevation of cellular cAMP or inhibit non-CFTR Cl(-) channels, multidrug resistance protein-1 (MDR-1), ATP-sensitive K(+) channels, or a series of other transporters. A single intraperitoneal injection of CFTR(inh)-172 (250 micro g/kg) in mice reduced by more than 90{\%} cholera toxin-induced fluid secretion in the small intestine over 6 hours. Thiazolidinone CFTR inhibitors may be useful in developing large-animal models of cystic fibrosis and in reducing intestinal fluid loss in cholera and other secretory diarrheas.

更多信息

更多信息
Molecular Weight 409.4 g/mol
Alternative Names Cystic fibrosis transmembrane conductance regulator inhibitor 172; CFTR Inhibitor-172
Cas Number 307510-92-5
Chemical Formula C18H10F3NO3S2
纯度 ≥ 98%
质量保证:

产品仅供研究使用,不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息,请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.